At last week’s American Academy of Dermatology (AAD) Association Annual Meeting, consumer health company Kenvue, Inc., which includes brands like Neutrogena and Aveeno, showcased 22 new sets of clinical data which contribute “to the advancement of everyday skin care,” said a Kenvue press release.
“In findings from the 22 data sets detailing new Kenvue skin science research,” the release continued, “industry experts [presented] evidence confirming the clinical effectiveness of Neutrogena and Aveeno formulations in moisturizing skin, improving skin barrier, protecting against UVA sun damage, and rapidly reducing facial acne.”
Studies and findings on oat-containing moisturizers
As confirmed by Kenvue’s press release, six new clinical studies presented at last week’s AAD Annual meeting confirmed that “Kenvue investigators found that oat-containing moisturizers developed by Aveeno and Neutrogena scientists made the skin’s microbiome more resilient in a variety of populations,” which included “young children predisposed to eczema, women with dry skin, adults with mild to moderate eczema, and adults receiving immunobiological treatment for psoriasis.”
In one of these studies, authored by Insel RA, et al., researchers investigated colloidal oatmeal as a topical ingredient to prevent and treat dry, itchy skin. They determined that the infant skin microbiome is associated with a decreased risk of atopic dermatitis, stated a separate Kenvue press release.
In the study, “to explore a potential prevention strategy, investigators recommended the twice daily application of an oat- and glycerin-containing emollient to children in this population from birth through the age of eight weeks.”
The researchers concluded that “compared with a control group, DNA sequencing of skin microbiome samples collected from the cheeks and elbows showed that children treated with the emollient from birth to two months enjoyed lasting effects, with greater abundance of skin-health associated microflora and a lower risk of developing eczema at ages six and twelve months.”
A different study from the set, authored by Renno I et al., focused on the benefits of continuous oat-containing moisturizer usage in psoriasis patients undergoing immunobiological therapy.
“Psoriasis can impact patients’ quality of life due to itchy skin lesions and self-consciousness about appearance,” researchers stated. " But in this large study of patients receiving an immunobiological treatment for the chronic condition, most reported that concomitant self-care with an oat-containing moisturizer contributed to their well-being and improved their complexion.”
The study’s results “satisfied HCP [health care provider] requests for evidence demonstrating the efficacy of such a moisturizer in this population of patients,” the Kenvue press release detailed.
“Across these studies,” the release summarized, “findings showed that consumers enjoyed improved quality of life while using the moisturizing formulations — and, in many cases, for days afterwards or even longer.”
Other AAD data presentations
Additional data presented at AAD’s 2024 Annual Meeting demonstrated “the benefits of Kenvue’s formulations for skin hydration, sun protection and acne control,” the press release continued.
For example, a study authored by Kosmoski G. et al. on hydrocolloid patches efficacy as an acne treatment was based on the observation that “people with acne often become frustrated and noncompliant when using traditional over the counter and prescription acne treatments, as these solutions can take a long time to become effective,” the release said.
To examine consumer use of hydrocolloid patches, researchers conducted “a randomized trial of the Neutrogena Stubborn Acne Hydrocolloid Patch in people with mild to moderate acne,” the release confirmed.
The press release reported that “the research team found that those who used the patches perceived a noticeable reduction in the size, texture, and redness of both closed and popped pimples within a day compared with those who did not use the patches,” and “they concluded that these non-medicated patches are an effective option for overnight improvements to acne.”
About Kenvue’s participation at AAD, Adam Ricciardone, Head of R&D, Global Skin Health & Beauty and Head of R&D North America at Kenvue, shared in the company’s press release that it was “our first time presenting as Kenvue at the annual AAD meeting, allowing us a great opportunity to meet with leaders across dermatology and share our latest category-defining research that supports the value of our iconic brands as a part of everyday care.”
Further, he concluded,” the evidence presented illustrated “our ongoing commitment to delivering science-backed, care-forward experiences that are loved by consumers and recommended by healthcare professionals and experts.”